Show simple item record

dc.contributor.authorBrada, Men_US
dc.contributor.authorViviers, Len_US
dc.contributor.authorAbson, Cen_US
dc.contributor.authorHines, Fen_US
dc.contributor.authorBritton, Jen_US
dc.contributor.authorAshley, Sen_US
dc.contributor.authorSardell, Sen_US
dc.contributor.authorTraish, Den_US
dc.contributor.authorGonsalves, Aen_US
dc.contributor.authorWilkins, Pen_US
dc.contributor.authorWestbury, Cen_US
dc.date.accessioned2018-09-12T11:47:25Z
dc.date.issued2003-12en_US
dc.identifier12en_US
dc.identifier.citationANNALS OF ONCOLOGY, 2003, 14 pp. 1715 - 1721en_US
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2663
dc.identifier.doi10.1093/annonc/mdg371en_US
dc.description.abstractBackground: The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade 11 gliomas treated with surgery alone using imaging and clinical criteria. Patients and methods: Thirty patients with histologically verified WHO grade 11 gliomas (17 astrocytoma, I I oligodendroglioma, two mixed oligoastrocytoma) following surgery 2-104 months (median 23 months) after initial diagnosis received temozolomide 200 mg/m(2)/day for 5 days, on a 28-day cycle, for a maximum of 12 cycles or until tumour progression. Median age was 40 years (range 25-68 years). Median follow-up from entry into the study was 3 years [range 23-47 months (for patients alive)]. Objective response was assessed by 3-monthly magnetic resonance imaging and monthly health-related quality of life (HQoL) and clinical assessment. Tumour size was measured as the high signal intensity area on fluid attenuated inversion recovery sequences. Responses were assessed using change in the product of two perpendicular diameters as complete response (CR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD). Results: Twenty-nine of 30 patients entered into the study were evaluable for response. Three patients had a PR, 14 MR, I I SD and one PD. Twenty-four patients received 12 cycles of chemotherapy. Of 29 evaluable patients, three discontinued after four, five and six cycles and two after 10 cycles. Nine patients progressed (three during chemotherapy-one PD and two initial SD-and six after completion of chemotherapy); five had evidence of transformation. The 3-year progression-free survival was 66%. Five patients died; the actuarial 3-year survival was 82%. Ninety-six per cent of patients with impaired HQoL had improvement in at least one HQoL domain. There was improvement in 115 of the 207 domains (56%). Fifteen of 28 patients (54%) with epilepsy had reduction in seizure frequency, of whom six became seizure free. Six patients had transient grade III/IV haematological toxicity (11 episodes; 3.5%). Conclusions: Temozolomide has single-agent activity in patients with WHO grade 11 cerebral glioma, with modest improvement in quality of life and improvement in epilepsy control. On present evidence, temozolomide cannot be considered as primary therapy without formal comparison with other treatment modalities.en_US
dc.format.extent1715 - 1721en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherOXFORD UNIV PRESSen_US
dc.titlePhase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomasen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdg371en_US
rioxxterms.licenseref.startdate2003-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfANNALS OF ONCOLOGYen_US
pubs.notesaffiliation: Brada, M (Reprint Author), Inst Canc Res, Acad Unit Radiotherapy & Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England. Inst Canc Res, Acad Unit Radiotherapy & Oncol, Sutton SM2 5PT, Surrey, England. Royal Marsden NHS Trust, Neurooncol Unit, Sutton SM2 5PT, Surrey, England. Royal Marsden NHS Trust, Dept Comp, Sutton SM2 5PT, Surrey, England. Atkinson Morleys Hosp, London, England. keywords: chemotherapy; low-grade glioma; temozolomide keywords-plus: PROGNOSTIC-FACTORS; RECURRENT OLIGODENDROGLIOMA; GLIOBLASTOMA-MULTIFORME; RANDOMIZED-TRIAL; PCV CHEMOTHERAPY; 1ST RELAPSE; EFFICACY; PROCARBAZINE; SURVIVAL; OLIGOASTROCYTOMA research-areas: Oncology web-of-science-categories: Oncology number-of-cited-references: 24 times-cited: 173 usage-count-last-180-days: 1 usage-count-since-2013: 5 journal-iso: Ann. Oncol. doc-delivery-number: 756UA unique-id: ISI:000187500600004 oa: gold_or_bronze da: 2018-09-11en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume14en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record